Business Context and Reporting Period
This Form 6-K filing by Ping An Biomedical Co., Ltd. covers the month of October 2025, specifically dated October 14, 2025. The report details a comprehensive restructuring of the Company's senior leadership and Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change is the immediate resignation of the entire existing senior leadership team and several board members, followed by the appointment of new officers effective October 14, 2025.
- Resignations: Ms. Yuk Yin Judy Li (Chairman and Director), Ms. Lina Jiang (Director and CEO), Ms. Xueyuan Chen (CFO), and Mr. Taylor Carl Coplen (Independent Director). All resigned for personal reasons with no stated disagreement regarding operations or policies.
- Appointments:
- Mr. Pijun Liu: Appointed Chairman, CEO, and Executive Director.
- Ms. Hongli Yang: Appointed Chief Financial Officer.
- Mr. Xianzhi Liu: Appointed Independent Director.
Outlook, Risks, and Management Commentary
The filing does not provide financial guidance, market outlook, or specific risk factors related to business operations. Management commentary is limited to the biographical backgrounds of the new appointees:
- Mr. Pijun Liu: Holds a master's degree from the University of Arizona and an EMBA from Tsinghua. Previously founded and served as CEO of Yueshang Group (2014-2023) and worked at ELong.com.
- Ms. Hongli Yang: Holds a bachelor's degree in Financial Management. Previously served as CFO for Softcom Information Technology, Beijing Sinobo, and Huibo Cloud Communication Technology since 2021.
- Mr. Xianzhi Liu: Holds a master's degree from the University of Leeds. Previously worked at JD.com, Beijing New Oriental, and New Channel.
Key Facts for Investor Verification
- Verify the immediate effectiveness of the leadership transition on October 14, 2025.
- Confirm that the resignations were voluntary and not related to any undisclosed disputes or regulatory issues.
- Assess the operational continuity plan given the simultaneous departure of the Chairman, CEO, and CFO.
- Review the new management team's experience in the biomedical sector, as their backgrounds appear focused on technology, e-commerce, and education.